Bailey R. A. 1 , Vijapurkar U. 2 , Martin S. 1 , Meininger G. 2 , Rupnow M. F. 1 1 Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 2 Janssen Research and Development, Raritan, NJ, USA Objectives: Public and private US Payers use CQM to assess the quality of diabetes care and to incentivize improvement in care and associated outcomes. Examples of payers using CQMs include the Medicare Shared Savings Program (MSSP) and HealthPartners (HP). This post hoc analysis assessed CQM attainment with CANA and SITA in overweight/obese patients with T2DM. MethOds: This analysis used pooled data from 2 previously published comparative randomized controlled clinical trials that evaluated CANA and SITA treatment in patients with inadequate glycemic control on current therapy. CQM attainment was defined as achievement of combined glycated hemoglobin (HbA1c), blood pressure, and low density lipoprotein cholesterol (LDL-C) thresholds. CQM attainment was assessed at baseline and 52 weeks, using last observation carried forward. Differences between CANA and SITA treatment groups were evaluated using 95% confidence intervals (CI) and odds ratios (OR) based on logistic regression. Results: Baseline characteristics of 645 CANA and 649 SITA treated patients with body mass index > 25 kg/m4 2 and data for CQM assessment were similar. Baseline CQM attainment was similar between groups. At 52 weeks, CANA vs SITA demonstrated a greater likelihood of attaining CQMs. For the HP CQM HbA1c< 7%;BP< 130/80mmHg;LDL-C< 100mg/dL, CANA demonstrated 4.9% (95% CI 1.2;8.5 and OR 1.94, 95% CI 1.30;2.91 ) better attainment. For the MSSP CQM HbA1c< 8%;BP< 140/90mmHg;LDL-C< 100mg/dL CANA demonstrated 6.6% (95% CI 1.4;11.9 and OR 1.58, 95% CI 1.19;2.08) better attainment. Hypoglycemia rates for each group were similar. CANA was associated with higher rates of genital mycotic infections and adverse events related to osmotic diuresis, but with few study discontinuations. cOnclusiOns: Compared to SITA 100 mg, CANA 300 mg treatment was associated with better CQM attainment in obese/overweight patients with T2DM. This information may inform payers on the comparative effectiveness of antihyperglycemic agents on attainment of diabetes CQMs which include glycemic, blood pressure, and lipid endpoints. Objectives: The objective was to examine the evidence on the efficacy of current treatments in patients with Cushing's disease (CD) to support health care decisionmaking. MethOds: A systematic literature search using predefined strategy was performed in the Cochrane library, EMBASE, PUBMED and MEDLINE to identify observational studies in North America and Europe from 2003 to 2013. A total of 32 studies were included and analyzed, out of 791 studies found. Results: For primary CD (n= 23/32), transsphenoidal surgery (TSS) remains the procedure of choice (n= 20/23, 87% of studies). For recurrent/persistent disease (n= 11/32), treatment received was; TSS in 36.3%, radiotherapy in 27.35%, bilateral adrenalectomy (BLA) in 18.2% and medical therapy in 18.2%. Remission rates post primary TSS were 65%-91% with recurrence of 5%-24%. Variability in remission rate could be attributed to the lack of uniformity in the definition for remission, different length of follow-up, patient population (macro-vs. micro-adenomas), surgeon experience and the type of TSS technique used (endoscopic vs. microscopic). Remission rate was lower for recurrent/persistent CD (37.5%-71%).Major complications were; diabetes
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Objectives: The discussion around the cardiovascular risk caused by rosiglitazone continues, as the results from recent pharmacoepidemiologic studies were believed inconclusive. The objective of this study is to do a descriptive study on the adverse events, especially cardiovascular events caused by rosiglitazone and other commonly used anti-diabetes agents. MethOds: FDA adverse event reporting system (FAERS) database was used for data analysis; reports were drawn from 1997 to 2011. Study drugs include rosiglitazone, pioglitazone, metformin, glipizide and glyburide. Adverse events during time were calculated to see the trend. Frequency of different adverse events described and stratified by age and gender. Different outcomes like the cardiovascular events, death and hospitalization associated with each study drug were calculated each year. Results: The adverse events of all drugs did not vary much during years, except that rosiglitazone has a sharply increase from 2008 and decreased in 2011, in accordance with the 2007 meta-analysis published. Adverse events of different drugs differ in gender: there are 10% more adverse events of glyburide and 14% more of rosiglitazone in male than female; while metformin cause 8% more in female than male. Rosiglitazone has significantly more deaths (5568) and hospitalizations (28387) comparing to other four drugs (average 2225 death and 11521 hospitalization), and it also has more cardiovascular events (36.37%) than other four drugs (average 11.52%). cOnclusiOns: Rosiglitazone seems to have more and severe adverse events, especially cardiovascular events comparing to other four antidiabetic drugs. Objectives: Intramuscular (IM) testosterone injections have been available since 1953 but significant immediate adverse reactions have not been well documented. The objective was to estimate the rate of anaphylaxis associated with IM testosterone injections. MethOds: This retrospective analysis utilized a large commercial claims database. Study sample consisted of males who received office-based IM testosterone injection(s) between 2007 and 2011. Anaphylaxis cases were selected from medical claims based on the ICD-9-CM 995.0 (other anaphylactic reaction), occurring on the same day of the testosterone injection. The relationship between testosterone injections and anaphylaxis were classified as "likely, probably, possible, unlikely" based on the clinical review of patient's medical history, treatment for anaphylaxis and existence of confounding diagnoses. The outcomes were the number of patients with anaphylaxis per 10,000 patients and the number of anaphylaxis cases per 10,000 person-years. Results: Between 2007 and 2011, 989,778 IM testosterone injections were identified for a total of 120,402 males (mean age: 49.1 years). A total of 232 patients had at least one anaphylaxis claim within 365 days of receiving an IM testosterone injection. Among 40 same-day anaphylaxis cases (39 patients), there were 12 cases (12 patients) with anaphylaxis classified as "likely" or "probable", which represent a rate of 1.0 patient per 10,000 patients, or 1.5 cases per 10,000 person-years. There were 17 cases (16 patients) with anaphylaxis classified as "likely", "probable", or "possible". In comparison, there were only 19 cases of anaphylaxis identified from the FDA Adverse Event Reporting System (FAERS) from 1/1969 to 1/2013 (44 years). cOnclusiOns: Our study showed that, although rare, anaphylaxis-related events have been documented to occur following IM testosterone injections. Given the limitations of spontaneous reporting of adverse events for marketed products, claims databases can be utilized to complement FAERS in identifying safety signals for drugs, especially older drugs. Objectives: To assess clinical outcomes among individuals having chronic illness with complexity (CIC) defined as co-occurring type 2 diabetes mellitus (T2DM) and Parkinson's disease (PD). MethOds: This study used a retrospective cohort design using Humana Medicare Advantage Part D claims database (2007) (2008) (2009) (2010) (2011) and included elderly (age ≥ 65 years) Medicare beneficiaries with T2DM (identified by ICD-9-CM code of 250.x0 or 250.x2). PD was identified using ICD-9-CM code of 332. xx. Individuals with T2DM and PD (CIC) were matched to those with T2DM and no PD (no CIC) on sex, age, and diabetes complications severity index based on 8 to 1 GREEDY matching algorithm using propensity score. After propensity score matching there were 2,703 individuals with T2DM and PD and 8,109 with T2DM and no PD. Glycemic control outcomes [(i) < 8%, (ii) ≥ 8%, (iii) no HbA1c values] and lipid control outcomes [based on Low Density Lipoprotein Cholesterol (LDL-C) categorized into (i) < 100 mg/dl, (ii) ≥ 100mg/dl, (iii) no LDL-C values] were measured during the year subsequent to the identification of T2DM and PD. Multinomial conditional logistic regressions were conducted to examine the association between PD and clinical outcomes. Results: Among those with laboratory values, 86.1% individuals with PD and 83.8% individuals without PD had < 8% HbA1c value; the corresponding figures for LDL-C value of < 100mg/dl were 75.5% and 69.8% respectively. Multinomial conditional logistic regressions revealed that individuals with PD were more likely than those without PD to have good glycemic control of < 8% HbA1c (reference group: ≥ 8% HbA1c) (AOR: 1.34, 95%CI: 1.10-1.63) and good LDL-C control of < 100mg/dl (reference group: ≥ 100mg/dl LDL-C) (AOR: 1.29, 95%CI: 1.03-1.63). cOnclusiOns: Individuals with CIC were more likely to have clinically recommended glycemic and
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